Search results for "Bioequivalence"

showing 10 items of 50 documents

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.

2019

Literature data and results of experimental studies relevant to the decision to allow waiver of bioequivalence studies in humans for the approval of immediate release solid oral dosage forms containing cephalexin monohydrate are presented. Solubility studies were performed in accordance with the current biowaiver guidelines of the Food and Drug Administration, World Health Organization and European Medicines Agency, taking the degradation at some pH values into consideration. Together with solubility and permeability data for cephalexin monohydrate from the literature, it was demonstrated to be a Biopharmaceutics Classification System Class 1 drug. The pharmacokinetic behavior, results of b…

Drugmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicinemedicineBiopharmaceutics Classification System (BCS)HumansRegulatory scienceLADME characteristicsmedia_commonActive ingredientcephalexin monohydrateDosage FormsbioequivalenceCephalexinexcipientsbusiness.industryBiopharmaceutics021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.

2015

Abstract Nanomedicines are more complex than most pharmacologically active substances or medicines and have been considered as non-biological complex drugs. For nanomedicines pivotal pharmacokinetic properties cannot be assessed by plasma concentration data from standard bioequivalence studies. Using intravenous iron complexes (IICs) as model we show that fetal avian tissues can be used to study time dependent tissue concentrations in heart and liver. Clear differences were found between equimolar doses of sucrose, gluconate or carboxymaltose coated iron particles. The range in tissue iron concentrations observed with these clinically widely used IICs provides an orientation as to what shou…

FetusExperimental modelbusiness.industryIronTissue ironAuthorizationIntravenous ironHeartGeneral MedicineBioequivalencePharmacologyToxicologyNanomedicineLiverTherapeutic EquivalencyPharmacokineticsAnimalsDrugs GenericMedicineAdministration IntravenousTissue DistributionTissue distributionbusinessChickensIron CompoundsRegulatory Toxicology and Pharmacology
researchProduct

In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluis…

2015

Intestinal drug permeability has been recognized as a critical determinant of the fraction dose absorbed, with direct influence on bioavailability, bioequivalence and biowaiver. The purpose of this research was to compare intestinal permeability values obtained by two different intestinal rat perfusion methods: the single-pass intestinal perfusion (SPIP) model and the Doluisio (closed-loop) rat perfusion method. A list of 15 model drugs with different permeability characteristics (low, moderate, and high, as well as passively and actively absorbed) was constructed. We assessed the rat intestinal permeability of these 15 model drugs in both SPIP and the Doluisio methods, and evaluated the co…

In situMaleSingle passIntestinal permeabilitybusiness.industryPharmaceutical ScienceBioequivalencePharmacologymedicine.diseaseBiopharmaceutics Classification SystemModels BiologicalPermeabilityBioavailabilityRatsPerfusionPermeability (earth sciences)Intestinal AbsorptionPharmaceutical PreparationsmedicineAnimalsHumansIntestinal MucosaRats WistarbusinessPerfusionInternational journal of pharmaceutics
researchProduct

Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.

2018

Regulatory guidelines recommend that, when a level A IVIVC is established, dissolution specification should be established using averaged data and the maximum difference between AUC and Cmax between the reference and test formulations cannot be greater than 20%. However, averaging data assumes a loss of information and may reflect a bias in the results. The objective of the current work is to present a new approach to establish dissolution specifications using a new methodology (individual approach) instead of average data (classical approach). Different scenarios were established based on the relationship between in vitro-in vivo dissolution rate coefficient using a level A IVIVC of a cont…

In vitro dissolutionCmaxPharmaceutical Science02 engineering and technologyBioequivalence021001 nanoscience & nanotechnology030226 pharmacology & pharmacyControlled releaseModels Biological03 medical and health sciencesDrug Liberation0302 clinical medicineIVIVCTherapeutic EquivalencyDelayed-Action PreparationsMaximum differenceRange (statistics)Computer Simulation0210 nano-technologyBiological systemDissolutionMonte Carlo MethodMathematicsTabletsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential …

2018

The accuracy of the provisional estimation of the Biopharmaceutics Classification System (BCS) is heavily influenced by the permeability measurement. In this study, several theoretical and experimental models currently employed for BCS permeability classification have been analysed. The experimental models included the in situ rat intestinal perfusion, the ex vivo rat intestinal tissue in an Ussing chamber, the MDCK and Caco-2 cell monolayers, and the parallel artificial membrane (PAMPA). The theoretical models included the octanol-water partition coefficient and the QSPeR (Quantitative Structure-Permeability Relationship) model recently developed. For model validation, a dataset of 43 comp…

In vitro dissolutionTheoretical modelsPharmaceutical Science02 engineering and technologyBioequivalenceIn Vitro TechniquesWorld Health Organization030226 pharmacology & pharmacyModels BiologicalDosage formPermeabilityBiopharmaceuticsMadin Darby Canine Kidney Cells03 medical and health sciences0302 clinical medicineDogsAnimalsHumansPharmacology (medical)Intestinal MucosaMathematicsPharmacologyGeneral Medicine021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemBioavailabilityRatsPermeability (earth sciences)BiopharmaceuticalCaco-2 Cells0210 nano-technologyBiological systemDrugs EssentialBiopharmaceuticsdrug disposition
researchProduct

Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker 51Cr-EDTA

2017

There is a renewed interest from the pharmaceutical field to develop oral formulations of compounds, such as peptides, oligonucleotides, and polar drugs. However, these often suffer from insufficient absorption across the intestinal mucosal barrier. One approach to circumvent this problem is the use of absorption modifying excipient(s) (AME). This study determined the absorption enhancing effect of four AMEs (sodium dodecyl sulfate, caprate, chitosan, N-acetylcysteine) on five model compounds in a rat jejunal perfusion model. The aim was to correlate the model compound absorption to the blood-to-lumen clearance of the mucosal marker for barrier integrity, 51Cr-EDTA. Sodium dodecyl sulfate a…

KetoprofenFysiologiPhysiologyabsorption modifiersPharmaceutical ScienceExcipient51cr edtaPharmacology and Toxicology02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyChitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicineintestinal perfusionDrug DiscoverymedicineIntestinal transportSodium dodecyl sulfatebioequivalenceChromatographypermeation enhancersPermeationFarmakologi och toxikologi021001 nanoscience & nanotechnologypharmaceutical developmentchemistryMolecular Medicine0210 nano-technologymedicine.drugMolecular Pharmaceutics
researchProduct

Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients.

2015

The objective of this paper was to validate a previously developed semi physiological model to simulate bioequivalence trials of drug products. The aim of the model was to ascertain whether the measurement of the metabolite concentration-time profiles would provide any additional information in bioequivalence studies (Fernandez-Teruel et al., 2009a,b; Navarro-Fontestad et al., 2010). The semi-physiological model implemented in NONMEM VI was used to simulate caffeine and its main metabolite plasma levels using caffeine parameters from bibliography. Data from 3 bioequivalence studies in healthy subjects at 3 different doses (100, 175 and 400mg of caffeine) and one study in cirrhotic patients …

Liver CirrhosisMetabolitePopulationPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalIntestinal absorptionchemistry.chemical_compoundPharmacokineticsCaffeineMedicineHumansComputer SimulationeducationBiotransformationParaxanthineeducation.field_of_studyDose-Response Relationship Drugbusiness.industryReproducibility of ResultsHealthy VolunteersNONMEMchemistryIntestinal AbsorptionTherapeutic EquivalencyCentral Nervous System StimulantsCaffeinebusinessAlgorithmsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs.

2018

Pharmaceutical excipients that may affect gastrointestinal (GI) drug absorption are called critical pharmaceutical excipients, or absorption-modifying excipients (AMEs) if they act by altering the integrity of the intestinal epithelial cell membrane. Some of these excipients increase intestinal permeability, and subsequently the absorption and bioavailability of the drug. This could have implications for both the assessment of bioequivalence and the efficacy of the absorption-enhancing drug delivery system. The absorption-enhancing effects of AMEs with different mechanisms (chitosan, sodium caprate, sodium dodecyl sulfate (SDS)) have previously been evaluated in the rat single-pass intestin…

MalePharmaceutical ScienceExcipientBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyIntestinal absorptionPermeabilityExcipients03 medical and health sciences0302 clinical medicineDogsIn vivomedicineAnimalsPharmaceutical sciencesIntestinal MucosaChitosanIntestinal permeabilityChemistrySodium Dodecyl Sulfate021001 nanoscience & nanotechnologymedicine.diseaseBioavailabilityRatsIntestinesIntestinal AbsorptionPharmaceutical PreparationsDrug delivery0210 nano-technologyDecanoic Acidsmedicine.drugInternational journal of pharmaceutics
researchProduct

Medroxyprogesterone acetate: steady-state pharmacokinetics bioequivalence of two oral formulations

1989

Two micronized oral formulations of medroxyprogesterone acetate (MPA) (Farlutal and Clinovir) were compared in order to evaluate their relative bioavailability. Sixteen female patients with metastatic breast cancer were entered in a randomized cross-over study on 500-mg MPA tablets repeatedly administered (twice daily for 20 days). At the steady state, similar mean +/- SD serum levels of MPA were obtained (131 +/- 44 ng/ml for Farlutal and 136 +/- 45 ng/ml for Clinovir) and the two formulations proved to be bioequivalent (confidence interval at a significance level of 0.95 = 93%-107%).

MedroxyprogesteroneCancer Researchbusiness.industryMedroxyprogesteroneAdministration OralAntineoplastic AgentsMedroxyprogesterone AcetateGeneral MedicineMiddle AgedPharmacologyBioequivalenceConfidence intervalDosage formBioavailabilityTherapeutic EquivalencyOncologyPharmacokineticsOral administrationHumansMedicineMedroxyprogesterone acetateFemalebusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.

2019

Literature data pertaining to the physicochemical, pharmaceutical, and pharmacokinetic properties of ondansetron hydrochloride dihydrate are reviewed to arrive at a decision on whether a marketing authorization of an immediate release (IR) solid oral dosage form can be approved based on a Biopharmaceutics Classification System (BCS)-based biowaiver. Ondansetron, a 5HT3 receptor antagonist, is used at doses ranging from 4 mg to 24 mg in the management of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative treatment. It is a weak base and thus exhibits pH-dependent solubility. However, it is able to meet the criteria of "high solubility" as well as "high permeabi…

NauseaPharmaceutical ScienceAdministration OralBiological Availabilitydissolution02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formBiopharmaceuticsOndansetronExcipients03 medical and health sciencesondansetron hydrochloride dihydrate0302 clinical medicinePharmacokineticsMedicineHumansDissolution testingDosage FormsOndansetron hydrochloridebusiness.industrybiopharmaceutics classification system (BCS)solubility021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemOndansetronbiowaiverTherapeutic Equivalencymedicine.symptompermeability0210 nano-technologybusinessmedicine.drugTablets
researchProduct